Compare SRRK & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | DUOL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.9B |
| IPO Year | 2018 | 2021 |
| Metric | SRRK | DUOL |
|---|---|---|
| Price | $47.76 | $122.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 18 |
| Target Price | $56.17 | ★ $176.69 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 355.85 |
| EPS | N/A | ★ 0.89 |
| Revenue | N/A | ★ $1,037,589,000.00 |
| Revenue This Year | N/A | $18.93 |
| Revenue Next Year | $534.24 | $14.02 |
| P/E Ratio | ★ N/A | $135.58 |
| Revenue Growth | N/A | ★ 38.71 |
| 52 Week Low | $27.07 | $87.89 |
| 52 Week High | $58.49 | $468.00 |
| Indicator | SRRK | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 47.85 |
| Support Level | $45.46 | $102.19 |
| Resistance Level | $48.23 | $136.48 |
| Average True Range (ATR) | 2.44 | 6.33 |
| MACD | -1.01 | -1.45 |
| Stochastic Oscillator | 6.24 | 26.87 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.